Preventing and Treating Brain Metastases with Three First-Line EGFR-TKI in Patients with EGFR Mutation Advanced NSCLC

被引：0
|
作者：
Lin, C. [1 ]
Su, W. [1 ]
Wu, Y. [2 ]
机构：
[1] Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan
[2] Natl Cheng Kung Univ Hosp, Dept Nursing, Tainan, Taiwan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
Brain metastasis; tyrosine kinase inhibitor; EGFR mutation;
D O I：
10.1016/j.jtho.2018.08.616
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-60
引用
收藏
页码：S484 / S484
页数：1
相关论文
共 50 条
  • [1] Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC
    Fiala, O.
    Pesek, M.
    Finek, J.
    Benesova, L.
    Bortlicek, Z.
    Minarik, M.
    NEOPLASMA, 2013, 60 (04) : 425 - 431
  • [2] CLINICAL OUTCOMES AFTER FIRST-LINE EGFR-TKI FOR PATIENTS WITH NSCLC, EGFR MUTATION, AND POOR PERFORMANCE STATUS
    Nagamata, Makoto
    Okuma, Yusuke
    Sunami, Kuniko
    Hosomi, Yukio
    Okamura, Tatsuru
    ANNALS OF ONCOLOGY, 2014, 25
  • [3] EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases
    Dong, Kai
    Liang, Wenhua
    Zhao, Shen
    Guo, Minzhang
    He, Qihua
    Li, Caichen
    Song, Haiqing
    He, Jianxing
    Xia, Xiaojun
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (03) : 268 - +
  • [4] Usage of EGFR-TKI and WBRT in NSCLC patients with brain metastases
    Chen, Yuh-Min
    ANNALS OF PALLIATIVE MEDICINE, 2013, 2 (03) : 108 - 110
  • [5] Retreatment with EGFR-TKI for 541 NSCLC Patients with EGFR Mutation
    Takahashi, K.
    Ito, K.
    Murotani, K.
    Asada, K.
    Okuno, M.
    Kimura, T.
    Kubo, A.
    Suda, T.
    Taniguchi, H.
    Hataji, O.
    Shindo, J.
    Kunii, E.
    Yoshida, T.
    Imaizumi, K.
    Hida, T.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S833 - S833
  • [6] Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for advanced NSCLC with EGFR-positive mutation patients: A systematic review
    Chen, S.
    Marcella, E.
    Susanto, B.
    Tandiono, J.
    Heriyanto, R. S.
    Wijovi, F.
    Tancherla, A.
    Kurniawan, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S779 - S780
  • [7] EGFR-TKI Plus Brain Radiotherapy Versus EGFR-TKI Alone in the Management of EGFR Mutated NSCLC Patients with Brain Metastases: A Meta-Analysis
    Xia, X.
    Guo, M.
    He, J.
    Liang, W.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S382 - S382
  • [8] The Third Generation EGFR Inhibitor (EGFR-TKI) HS-10296 in Advanced NSCLC Patients with Resistance to First Generation EGFR-TKI
    Lu, S.
    Wang, Q.
    Zhang, G.
    Dong, X.
    Yang, C.
    Song, Y.
    Chang, G.
    Lu, Y.
    Pan, H.
    Chiu, C.
    Wang, Z.
    Feng, J.
    Zhou, J.
    Xu, X.
    Guo, R.
    Chen, J.
    Yang, H.
    Chen, Y.
    Yu, Z.
    Shiah, H.
    Wang, C.
    Yang, N.
    Fang, J.
    Wang, P.
    Wang, K.
    Hu, Y.
    He, J.
    Wang, Z.
    Shi, J.
    Chen, S.
    Cheng, Y.
    Su, W.
    Hsia, T.
    Cui, J.
    Sun, Y.
    Yang, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S208 - S209
  • [9] First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Wu, Qiang
    Luo, Wuxia
    Li, Wen
    Wang, Ting
    Huang, Lin
    Xu, Feng
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [10] Analysis of Efficacy and Safety of First Generation EGFR-TKI plus Apatinib in Treating Advanced NSCLC after EGFR-TKI Treatment Failure
    Feng, Y.
    Zhu, H.
    Hu, X.
    Liu, Y.
    Xing, P.
    Wang, H.
    Ji, X.
    Dai, Z.
    Shi, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S609 - S609
12345